Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
复制标题
DOI：
10.1200/jco.2011.37.0981
复制
发表时间：
2012-09-01
影响因子：
45.3
通讯作者：
Letai, Anthony
中科院分区：
文献类型：
--
作者：
Davids, Matthew S.;Letai, Anthony
B细胞淋巴瘤/白血病2(BCL-2)家族自25年前克隆BCL-2以来，一直受到肿瘤生物学家的关注。在接下来的几十年里，bcl2家族控制程序性细胞死亡的方式已经得到了很大的阐明。几种针对抑制bcl2和相关的抗凋亡蛋白的药物已经在临床上进行了测试，其中一些显示出相当大的希望，特别是在淋巴系统恶性肿瘤方面。对bcl2家族的更好理解也为传统化疗如何选择性地杀死癌细胞以及为什么一些癌症比其他癌症更敏感提供了洞察力。进一步利用我们对bcl2家族的理解有望为肿瘤学家提供更好的预测性生物标记物，并为癌症患者提供更好的治疗方法。J Clin Oncol30：3127-3135。(C)2012年美国临床肿瘤学会
The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer. J Clin Oncol 30: 3127-3135. (C) 2012 by American Society of Clinical Oncology